Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas

Gut

Volumn 64, Issue 11, 2015, Pages 1721-1731

  Lin, Suling J ^a   Gagnon Bartsch, Johann A ^b   Tan, Iain Beehuat ^c   Earle, Sophie ^d   Ruff, Louise ^d   Pettinger, Katherine ^d   Ylstra, Bauke ^e   Van Grieken, Nicole ^e   Rha, Sun Young ^f   Chung, Hyun Cheol ^f   Lee, Ju Seog ^g   Cheong, Jae Ho ^h   Noh, Sung Hoon ^h   Aoyama, Toru ⁱ   Miyagi, Yohei ⁱ   Tsuburaya, Akira ^j   Yoshikawa, Takaki ⁱ   Ajani, Jaffer A ^g   Boussioutas, Alex ^k,l   Yeoh, Khay Guan ^m   Yong, Wei Peng ⁿ   So, Jimmy ^m   Lee, Jeeyun ^o   Kang, Won Ki ^o   Kim, Sung ^o   Kameda, Yoichi ⁱ   Arai, Tomio ^p   Zur Hausen, Axel ^q,r   Speed, Terence P ^b,l,s   Grabsch, Heike I ^d,q,r   Tan, Patrick ^a,c,t,u   more..

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Yonsei University College of Medicine   (South Korea)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h Yonsei University College of Medicine   (South Korea)

ⁱ KANAGAWA CANCER CENTER   (Japan)

^j YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^k PETER MACCALLUM CANCER CENTRE   (Australia)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

ⁿ National University Cancer Institute   (Singapore)

^o Sungkyunkwan University School of Medicine   (South Korea)

^p Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology   (Japan)

^q MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^r MAASTRICHT UNIVERSITY   (Netherlands)

^s WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^t DUKE NUS MEDICAL SCHOOL   (Singapore)

^u NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD45 ANTIGEN; CD45RO ANTIGEN; CD66B ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CELL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUOROURACIL; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MISMATCH REPAIR; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; SURVIVAL TIME; T LYMPHOCYTE; TISSUE MICROARRAY; ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; MIDDLE AGED; STOMACH NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TRANSCRIPTOME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84947942506     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308252     Document Type: Article

References (51)

1. Ferlay J, Soerjomataram I, Ervik M, et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2013.
2. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
3. Lee WJ, Lee WC, Houng SJ, et al. Survival after resection of gastric cancer and prognostic relevance of systematic lymph node dissection: twenty years experience in Taiwan. World J Surg 1995;19:707-13.
4. Mok YJ, Koo BW, Whang CW, et al. Cancer of the stomach: a review of two hospitals in Korea and Japan. World J Surg 1993;17:777-82.
5. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995;333:32-41.
6. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000;88:921-32.
7. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomised, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-76.
8. Hecht JR, Bang YJ, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. [abstract] J Clin Oncol 2013;31(Suppl):LBA4001.
9. Azuma T. Helicobacter pylori CagA protein variation associated with gastric cancer in Asia. J Gastroenterol 2004;39:97-103.
10. Xue H, Lin B, Ni P, et al. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol 2010;25:1604-17.
11. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354-62.
12. Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012;61:673-84.
13. Dulak AM, Schumacher SE, van Lieshout J, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012;72:4383-93.
14. van Grieken NC, Aoyama T, Chambers PA, et al. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. Br J Cancer 2013;108:1495-501.
15. Su X, Zhan P, Gavine PR, et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer 2014;110:967-75.
16. Ossandon FJ, Villarroel C, Aguayo F, et al. In silico analysis of gastric carcinoma Serial Analysis of Gene Expression libraries reveals different profiles associated with ethnicity. Mol Cancer 2008;7:22.
17. Gagnon-Bartsch JA, Laurent J, and Speed TP. Removing Unwanted Variation from High Dimensional Data with Negative Controls. 2013. http://statistics.berkeley.edu/tech-reports/820
18. Gagnon-Bartsch JA, Speed TP. Using control genes to correct for unwanted variation in microarray data. Biostatistics 2012;13:539-52.
19. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
20. Wright A, Hutchins G, Randell R, et al. TMAi (Tissue MicroArray informatics): Using virtual slides and open standards to provide usability and interoperability for tissue microarrays in clinical trials. Liverpool, UK: 6th NCRI Cancer Conference, National Cancer Research Institute, 2010.
21. Zur Hausen A, van Rees BP, van Beek J, et al. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J Clin Pathol 2004;57:487-91.
22. Bouliotis G, Billingham L. Crossing survival curves: alternatives to the log-rank test. Trials 2011;12(Suppl 1):A137.
23. Rickman DS, Millon R, De Reynies A, et al. Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene 2008;27:6607-22.
24. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.
25. Sjodahl G, Lovgren K, Lauss M, et al. Infiltration of CD3 and CD68 cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumours. Urol Oncol 2014;32:791-7.
26. Eiro N, Pidal I, Fernandez-Garcia B, et al. Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumours on distant metastasis development in breast cancer. PLoS ONE 2012;7:e52796.
27. Bracci L, Schiavoni G, Sistigu A, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2014;21:15-25.
28. Grogg KL, Lohse CM, Pankratz VS, et al. Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol 2003;16:641-51.
29. Leung SY, Yuen ST, Chung LP, et al. Microsatellite instability, Epstein-Barr virus, mutation of type II transforming growth factor beta receptor and BAX in gastric carcinomas in Hong Kong Chinese. Br J Cancer 1999;79:582-8.
30. Nakamura S, Ueki T, Yao T, et al. Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Special reference to its detection by the polymerase chain reaction and in situ hybridization in 99 tumours, including a morphologic analysis. Cancer 1994;73:2239-49.
31. Landais E, Saulquin X, Houssaint E. The human T cell immune response to Epstein-Barr virus. Int J Dev Biol 2005;49:285-92.
32. Jie HB, Gildener-Leapman N, Li J, et al. Intratumoural regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013;109:2629-35.
33. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell 2008;133:775-87.
34. Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol 2000;53:255-61.
35. Camargo MC, Murphy G, Koriyama C, et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer 2011;105:38-43.
36. Perry S, de la Luz Sanchez M, Yang S, et al. Gastroenteritis and transmission of Helicobacter pylori infection in households. Emerg Infect Dis 2006;12:1701-8.
37. Sunakawa Y, Volz NB, Zhang W, et al. Genetic variants in tumour immune checkpoints as prognostic markers in patients (pts) with localised advanced gastric cancer (AGC). [abstract] J Clin Oncol 2014;32:5s(Suppl):4018.
38. Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005;2:98-107.
39. Bickenbach K, Strong VE. Comparisons of gastric cancer treatments: East vs. West. J Gastric Cancer 2012;12:55-62.
40. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2011. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975-2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
41. Camargo MC, Kim WH, Chiaravalli AM, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut 2014;63:236-43.
42. Bruchard M, Mignot G, Derangere V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumour growth. Nat Med 2013;19:57-64.
43. Wilke H, Van Cutsem E, Oh SC, et al. RAINBOW: A global, phase III, randomised, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). [abstract] J Clin Oncol 2014;32(Suppl 3):LBA7.
44. Mantovani A, Schioppa T, Porta C, et al. Role of tumour-associated macrophages in tumour progression and invasion. Cancer Metastasis Rev 2006;25:315-22.
45. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010;10:248-56.
46. Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58:808-14.
47. Shimizu M, Shimamura M, Owaki T, et al. Antiangiogenic and antitumour activities of IL-27. J Immunol 2006;176:7317-24.
48. Nikolinakos PG, Altorki N, Yankelevitz D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumour shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010;70:2171-9.
49. Shojaei F, Wu X, Malik AK, et al. Tumour refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nature Biotechnol 2007;25:911-20.
50. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
51. Moehler MH, Kim YH, Tan IB, et al. Sequential ipilimumab (Ipi) versus best supportive care (BSC) following first-line chemotherapy (Ctx) in patients (pts) with unresectable locally advanced or metastatic gastric or gastro-esophageal junction (GEJ) cancer: A randomised, open-label, two-arm, phase II trial (CA184-162) of immunotherapy as a maintenance concept. [abstract] J Clin Oncol 2013;31(Suppl): TPS4151.